Core Insights - The core product, the TUMAI® laparoscopic surgical robot, has surpassed 200 global commercial orders, covering nearly 50 countries and regions, with approximately 130 installations completed [1] - The significant increase in commercial orders and installations indicates the sustained and widespread recognition of TUMAI's clinical value globally, serving as a systematic certification of its safety, stability, and reliability [1] - Surgeons from various countries and medical systems are integrating TUMAI into their daily surgical practices and long-term academic development [1] Market Performance - Among the nearly 50 countries and regions covered, 12 have more than 5 orders, with strong growth in emerging markets such as India, Brazil, and Argentina; India has accumulated 14 orders, while Brazil has over 10 [1] - Developed markets continue to show breakthroughs, with Spain and Australia emerging as rapid growth points [1] - TUMAI's commercialization has established a new pattern of multi-regional collaborative resonance globally, spanning both emerging markets in developing countries and mature healthcare systems in developed nations [1] Clinical Application - TUMAI has made significant progress in the depth of single-center clinical applications, with several medical institutions having completed over 100 surgeries using TUMAI [1] - The application of TUMAI spans multiple specialties, including urology, general surgery, thoracic surgery, gynecology, pediatric surgery, and head and neck surgery [1] Remote Surgery Development - TUMAI is the first remote surgical robot system approved for commercial application, having received market approval in nearly 10 countries, including China, India, and Brazil [2] - The application of TUMAI covers regions where nearly half of the global population resides and has entered a phase of normalized and scaled clinical application [2] - As of now, TUMAI has completed nearly 800 remote surgeries across over 20 countries, maintaining a 100% success rate [2]